Evidence map›Paper›PMID 34834511›Full record

ArticleJournal of personalized medicine2021

Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler

Paschalis Steiropoulos, Stavros Tryfon, Christos Kyriakopoulos, Konstantinos Bartziokas, Konstantinos Kostikas

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02978703 (Non Interventional, Observational, Multi-center Study to Evaluate the Efficacy and Safety of Fluticasone/Salmeterol), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02978703 completednot on this map

Non Interventional, Observational, Multi-center Study to Evaluate the Efficacy and Safety of Fluticasone/Salmeterol (Rolenium / Elpenhaler Administration in Greek COPD Pattients

TypeobservationalSponsorElpen Pharmaceutical Co. Inc.Ran2017 to 2018Enrolled1,730ConditionsChronic Obstructive Pulmonary DiseaseArmsCOPD Pharmacologic Substance
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Paschalis SteiropoulosRespiratory Medicine Department, Faculty of Medicine, Democritus University of Thrace, 68131 Alexandroupolis, Greece.ORCID 0000-0001-7121-6253
Stavros TryfonRespiratory Medicine Department, "G. Papanikolaou" General Hospital of Thessaloniki, 57010 Thessaloniki, Greece.ORCID 0000-0001-5102-0480
Christos KyriakopoulosRespiratory Medicine Department, Faculty of Medicine, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0001-8806-2561
Konstantinos BartziokasRespiratory Medicine Department, Faculty of Medicine, University of Ioannina, 45500 Ioannina, Greece.
Konstantinos KostikasRespiratory Medicine Department, Faculty of Medicine, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-0774-3942
University of Ioannina · GRDemocritus University of Thrace · GRG. Papanikolaou General Hospital · GR

Funding

Elpen Pharmaceutical Co. Inc. Elpen Pharmaceutical Co. Inc.: NCT02978703
6 · The paper itself

Abstract

backgroundChronic Obstructive Pulmonary Disease (COPD) is an inflammatory lung disease characterized by airflow limitation that is not completely reversible. The fixed-dose combination of salmeterol and fluticasone propionate (SFC) has been approved as a treatment for COPD patients with a history of recurrent exacerbations and significant symptoms despite regular bronchodilator therapy. In the present study, we evaluated the change in FEV

methodsA 12-month multicenter prospective, observational study (NCT02978703) was designed. Data were collected during the enrollment visit (V0) and six (V1) and twelve months (V2) after the initiation of treatment with Elpenhaler

resultsIn total 1016 patients were enrolled, following usual daily clinical practice. A statistically significant improvement was observed in FEV

conclusionsCOPD patients treated for twelve months with SFC via the Elpenhaler

Indexed as

COPDFEV1mMRCsafety analysissalmeterol and fluticasone propionate fixed-dose combination

Identifiers

PMID34834511
PMCPMC8621702
OpenAlexW3213891634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.